Micofenolato De Mofetilo Cinfa

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Cinfa, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH USA supplies Micofenolato De Mofetilo Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in the management of immune‑mediated conditions where suppression of lymphocyte activity is required.

- Kidney transplant: helps prevent acute rejection of the transplanted organ. - Heart transplant: reduces the risk of early graft rejection. - Lupus nephritis: decreases renal inflammation and preserves kidney function.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may affect hydration. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: transient pain in the head region. - Vomiting: occasional expulsion of stomach contents. - Tremor: mild shaking of the hands or limbs.

Serious or Rare Side Effects: - Opportunistic infections: increased susceptibility to fungal, viral, or bacterial pathogens. - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia. - Malignancy: heightened risk of certain cancers with long‑term use. - Severe liver injury: elevated transaminases or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease. - Pregnancy complications: fetal toxicity and loss.

Patients should be monitored closely for safety concerns before and during therapy.

- Blood count monitoring: perform regular CBC to detect leukopenia or anemia. - Renal function assessment: evaluate serum creatinine and eGFR periodically. - Liver enzyme testing: check ALT/AST levels for hepatic toxicity. - Pregnancy avoidance: drug is category D; use effective contraception. - Dose adjustment in renal impairment: consider reduced dosing when clearance is decreased. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression increases risk of cytopenias. - Cyclosporine: raises mycophenolate exposure, potentially intensifying toxicity. - Tacrolimus: similar increase in systemic levels, requiring dose review. - Live vaccines: heightened risk of infection due to immunosuppression. - Cholesterol‑binding resins (e.g., cholestyramine): reduce mycophenolate absorption.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may lower oral bioavailability; separate dosing by at least 2 hours. - Rifampin: induces metabolism, decreasing mycophenolate concentrations. - Warfarin: possible increase in INR; monitor coagulation parameters. - ACE inhibitors: combined renal effects may require closer kidney function monitoring.